The Health and Human Services Department (HHS) has announced plans to slash 10,000 jobs and restructure its divisions under the leadership of Secretary Robert F. Kennedy Jr. This move is part of the broader efforts by the Trump administration to reduce the federal workforce and cut costs. The agency claims that laying off 10,000 federal workers would save $1.8 billion and not impact critical services.
In addition to the job cuts, the department will see a reduction in its workforce from 82,000 to 62,000, marking a nearly 25% decrease. HHS itself will undergo restructuring, going from 28 to 15 divisions. Several existing departments will be combined to form a new agency called the Administration for a Healthy America (AHA). This new agency will include key offices like the Office of the Assistant Secretary for Health, the Health Resources and Services Administration, and HHS’ substance use and occupational health offices.
Kennedy emphasized that the restructuring will eliminate redundant departments while preserving core functions. The move is in line with Kennedy’s focus on chronic diseases and his vision to “Make America Healthy Again.”
The announcement comes amidst other efforts to reduce the federal workforce, including early retirement and buyout offers. The Trump administration had previously laid off thousands of probationary workers in February, affecting various employees at HHS. The administration has also offered civil servants incentives to leave their posts and implemented a strict work-in-office policy that has led to low morale in agencies like the FDA and NIH.
Under Kennedy’s plan, the HHS’ Administration for Strategic Preparedness and Response will be transferred to the Centers for Disease Control and Prevention. This move will return control of the strategic national stockpile of medical and emergency supplies to the CDC.
The job cuts will impact various agencies within HHS, including the FDA, CDC, NIH, and Centers for Medicare and Medicaid Services. According to an HHS fact sheet, the cuts will affect approximately 19% of FDA employees, 18% of CDC employees, 6% of NIH employees, and 4% of CMS employees. The FDA assured that the cuts would not affect drug, medical device, or food reviewers, nor would it impact inspectors.
Former FDA head Robert Califf expressed concerns about the impact of the cuts on essential services and criticized the Trump administration for its treatment of employees. Despite the challenges, the Senate recently confirmed Marty Makary as FDA commissioner and Jay Bhattacharya as NIH director, ushering in a new era for these critical agencies. Lawmakers grilled Makary during his confirmation hearing regarding the recent budget cuts at the FDA, urging him to personally evaluate the agency’s personnel before any major layoffs. It remains unclear whether Makary had any influence over the decision to reduce staff at the FDA, especially since he had just assumed the position.
In response to the lawmakers’ concerns, Makary assured them that if confirmed as commissioner, he would conduct a thorough assessment of the staffing and personnel at the FDA. This commitment was made to address the fears surrounding the potential impact of the cuts on the agency’s effectiveness and ability to carry out its vital functions.
It is important to note that the FDA plays a crucial role in ensuring the safety and efficacy of medical products and food items in the United States. Any significant reduction in personnel could potentially hinder the agency’s ability to fulfill its regulatory responsibilities and protect public health.
The confirmation hearing highlighted the importance of maintaining a strong and competent workforce at the FDA to uphold its mission of safeguarding public health. Lawmakers emphasized the need for Makary to prioritize the well-being of FDA employees and ensure that any restructuring efforts are carried out thoughtfully and with careful consideration.
As the new commissioner of the FDA, Makary faces the challenging task of navigating the agency through a period of change and uncertainty. It is essential for him to demonstrate strong leadership and strategic decision-making to address the concerns raised by lawmakers and the public regarding the recent budget cuts and potential layoffs at the FDA.
In conclusion, Makary’s commitment to assessing the staffing and personnel at the FDA is a positive step towards addressing the challenges facing the agency. It is crucial for him to prioritize the agency’s workforce and ensure that any restructuring efforts are conducted in a manner that upholds the FDA’s mission of protecting public health. With the support of lawmakers and stakeholders, Makary can lead the FDA through this transitional period and strengthen its ability to fulfill its regulatory duties effectively.
